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Background: Disorders of cell adhesion are critical steps in cancer progression in which varieties of markers
including cadherins are involved in.Btbd7 was found to inhibit E-cadherin expression in MDCK cells and play
important roles during branching morphogenesis of embryonic salivary glands and lungs. However its function in
malignant tumors is largely unknown. The aim of this study is to investigate the clinicopathological significance and
possible function of Btbd7 in non-small cell lung cancer.
Methods: Immunohistochemistry and Western blotting were used to investigate Btbd7 expression in non-small cell
lung cancer and lung tissues. The clinicopathological association and the overall survival was analyzed. In vitro
experiments were performed using siRNA to investigate the function of Btbd7 in lung cancer cells.
Results: Btbd7 expression was elevated in non-small cell lung cancer tissues compared to normal lung tissues.
Increased Btbd7 expression was significantly associated with lymph node metastasis, reduced E-cadherin expression
and patients’ poor clinical outcome. Downregulation of Btbd7 expression in lung cancer cells by siRNA significantly
inhibits cancer cell invasion and effectively restores E-cadherin expression in cancer cell membrane.
Conclusions: Btbd7 contributes to reduced expression of E-cadherin and may be a promising cancer marker in
non-small cell lung cancer.
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The occurrence of invasion and metastasis of lung can-
cer cells are often the main difficulties in the treatment
of this tumor. Our previous studies have indicated that
abnormalities in cancer cell adhesion at the level of the
E-cadherin complex are involved in the invasion and
metastasis of lung cancer [1,2]. E-cadherin is one of the
key cadherins and plays major roles in the establishment
and maintenance of intercellular adhesion, cell polarity
and tissue architecture [3]. Abnormalities in expression,
cellular distribution and function of E-cadherin are fre-
quently indicated in development including invasiveness,* Correspondence: wangeh@hotmail.com
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unless otherwise stated.lymph node metastasis and distance metastasis in a variety
of human malignancies [4,5]. Various factors have been
found to regulate expression and function of E-cadherin
in malignant tumors and implicated in cancer progression
[6-14]. Recently Btbd7 (BTB (POZ) domain containing 7),
a BTB (POZ) domain containing protein, was found to
play important roles in the development of salivary glands
and lungs through regulating E-cadherin [15]. Many or-
gans form by branching of epithelia through the formation
of clefts and buds during embryonic development. The au-
thors identified Btbd7 as a dynamic regulator of branching
morphogenesis through its highly focal expression leading
to local regulation of E-cadherin and epithelial cell motility
[15]. Btbd7 protein contains 1130 amino acids with two
putative BTB/POZ domains. The protein family containing
BTB domains are evolutionarily conserved from Drosophila
to mammals [15]. The BTB domain is a protein-protein. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fan et al. BMC Cancer 2014, 14:704 Page 2 of 10
http://www.biomedcentral.com/1471-2407/14/704interaction motif that was first identified as a sequence
motif in genes of DNA virus [16]. The functions of BTB-
containing proteins well known now are mainly transcrip-
tional regulation and protein degradation [16]. Btbd7 was
originally indentified as a regulatory gene that promotes
epithelial tissue remodeling and formation of branched or-
gans [15]. However, it is still not clear whether Btbd7 is
also involved in the process of invasion and metastasis of
lung cancer cells. So far, expression of Btbd7 and its func-
tion in malignant tumors are largely unknown. The pur-
pose of this study is to investigate Btbd7 expression and
its clinicopathological significance in non-small cell lung
cancer (NSCLC). In addition, we used specific siRNA to
downregulate Btbd7 expression to investigate its possible
function to impact E-cadherin expression and invasion
ability in lung cancer cells in vitro.
Methods
Tissue samples
Tumor specimens including NSCLC tissues and paired
non-tumor portion (with >5 cm distance from the pri-
mary tumor’s edge) from 130 patients with NSCLC were
obtained between 2003 and 2009 following surgical re-
section at the First Affiliated Hospital of China Medical
University. Of the 130 lung cancer cases, 86 contained
complete follow-up data. None of the patients had re-
ceived radiotherapy, chemotherapy, or immunotherapy
prior to tumor excision. Of the patients, 87 are male and
43 are female, creating a 2.02:1 ratio of male to female.
Patients’ ages at the time of surgery ranged from 33 to
80, with an average age of 58.8 years old. The tumors
were classified according to the TNM stage revised by
the International Union Against Cancer (UICC) [17]. All
specimens were re-evaluated for diagnosis following the
criteria for classification of lung cancer by the World
Health Organization (WHO) [18] and the revised edition
for lung carcinoma in 2010 [19], and 62 squamous cell
carcinomas (SCCs) and 68 adenocarcinomas were con-
firmed. Relevant clinical data from the patients included
in the study can be seen in Additional file 1. This study
was approved by the Institutional Review Board of China
Medical University and conducted under the regulations
of it. Informed consent was obtained from all enrolled
patients prior to surgery.
Immunohistochemistry
Formalin-fixed, paraffin-embedded specimens were cut into
4 μm-thick sequential sections. The sections were dewaxed
in xylene and rehydrated stepwise in descending ethanol
series. Endogenous peroxidase activity and non-specific
binding were blocked with 3% H2O2 and non-immune sera,
respectively. The sections were then incubated with
primary goat anti-human polyclonal antibody Btbd7
(ab121006, abcam, HK; dilution 1:50), mouse anti-humanmonoclonal antibody E-cadherin (ab1416, abcam, HK;
dilution 1:100) and N-cadherin (ab98952, abcam, HK; di-
lution 1:100) overnight at 4°C. Thereafter, the catalyzed
signal amplification system (Maixin Biotechnology, Fuzhou,
Fujian, China) was used for staining of these proteins ac-
cording to the manufacturer’s instructions. The antibodies
were detected by a standard avidin-biotin complex method
with biotinylated secondary antibodies (Maixin) and an
avidin-biotin complex (Maixin), and developed with di-
aminobenzidine. Counterstaining was done lightly with
hematoxylin, and the sections were dehydrated in alco-
hol before mounting.
The sections were assessed by at least three observers
who had no knowledge of the patients’ clinical status and
independently from each other. Cases with discrepancies
were jointly re-evaluated by the investigators, and a con-
sensus was obtained. Scoring of IHC was based on two
parameters: the proportion of immunopositive cells and
their intensity of immunoreactivity. The proportion of
immunopositive cells was categorized as follows: 0: <10%;
1: ≥10% to <25%; 2: ≥25% to <50%; 3: ≥50% to <75% and
4: ≥75%. The staining intensity was categorized by relative
intensity as follows: 0: no positivity; 1: weak; 2: moderate
and 3: strong. A final immunoreactivity score of each sec-
tion was obtained by multiplying the two individual scores.
To obtain final statistical results, a final score less than 2
was considered as negative, while scores of 2 or more were
considered as positive. Membranous expression of E-
cadherin showed no significant variations in intensity of
staining, and the scoring system was applied based on
the percentage of positive cells: 0: <10%; 1: ≥10% to <25%;
2: ≥25% to <50%; 3: ≥50% to <75%, and 4: ≥75%. Since the
adjacent non-neoplastic bronchial epithelium had a score
of 4 for membranous localization of Ecadherin, cases with
scores <4 was defined as decreased Ecadherin expression,
while cases with a score of 4 were defined as preserved
E-cadherin expression.
Immunofluorescent staining
Cells were fixed with 4% paraformaldehyde, followed by
blocking with 1% BSA. They were then incubated with
mouse anti-human monoclonal antibody E-cadherin
(ab1416, abcam, HK; dilution 1:100) overnight at 4°C. The
primary antibodies were followed by incubation with sec-
ondary antibodies conjugated to rhodamine. The nuclei
were counterstained with DAPI. The cells were examined
with an Olympus IX51 fluorescent microscope (Olympus,
Tokyo, Japan), and images were captured with a CoolPIX
5400 camera (Nikon, Japan).
Western blotting
Tissues and cells were lysed in 10 volumes (w/v) of lysis
buffer. After centrifugation, the supernatant was col-
lected and quantified. The same amount of total protein
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PVDF membrane. The membrane was then incubated
overnight at 4°C with primary goat anti-human polyclonal
antibody Btbd7 (ab121006, abcam, HK; dilution 1:500) and
slug (sc-10436, Santa Cruz, USA, dilution 1:200), mouse
anti-human monoclonal antibody E-cadherin (ab1416,
abcam, HK; dilution 1:500), N-cadherin (ab98952, abcam,
HK; dilution 1:500) and GADPH (ab8245, Abcam, HK;
1:1000) and mouse anti-human polyclonal antibody β-actin
(ab20272, Abcam, HK; 1:500). After incubation with the
secondary antibody labeled with HRP at room temperature
for 2 h, protein bands were visualized using enhanced
chemiluminescence (ECL) and detected using the Bio-
Imaging System.
Cell culture and transfection
Human bronchial epithelial cell HBE, and lung carcinoma
cell lines including A549, NCI-H1299, NCI-H157, NCI-
H460, LH7, LTE and SPC were cultured in RPMI 1640
tissue culture medium (Invitrogen, Carlsbad, CA, USA),
containing 10% fetal calf serum (Invitrogen), 100 IU/mL
penicillin (Sigma, St Louis, MO, USA), and 100 μg/mL
streptomycin (Sigma) at 37°C in a humidified atmosphere
(5% CO2, 95% air). HBE, A549, NCI-H1299, NCI-H460
and NCI-H157 were obtained from the American Type
Culture Collection (Manassas, VA, USA). PG-LH7 (LH7)
was a gift from Professor Jie Zheng from Bejing University.
SPC-A-1 (SPC) and LTEP-A-2 (LTE) were obtained from
the cell bank of Chinese Academy of Science. Btbd7
siRNA (sc-92326) and negative control siRNA (sc-37007)
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). For transient transfection, the cells were
cultured in a 24-well plate for 24 h before the experiment.
Then the cells were transfected with Lipofectamine 2000
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. Following the transfection, the cells were
harvested at 24–48 hours to measure the protein levels.
Matrigel invasion assay
The cells’ invasive abilities were examined using a 24-well
Transwell with 8-μm pore polycarbonate membrane in-
serts (Corning, NY, USA) and matrigel (BD Bioscience) ac-
cording to the manufacturer’s instructions. 20 ul Matrigel
(1:3 dilution) was added to each insert. 100 ul cell suspen-
sion containing 3 × 105 cells cells was transferred to the
upper chamber and incubated for 36–48 h. The filters
were stained with hematoxylin. Cells that appeared on
the lower surface of the filter were counted in five ran-
dom high-magnification microscope. Each experiment
was done three times independently.
Scratch wounding assay
Cell suspension is added in 6-well plates. After mono-
layer of adherent cells is formed draw two vertical linesusing sterile 100 ul pipette tips then cells were washed 3
times with PBS to remove float cells from the mark.
Mitomycin C (1 ug/ml) (Sigma-Aldrich UK) was added
to the cells to inhibit cell proliferation 1 h before draw-
ing the lines.Then the plates are moved to an incubator
(5% CO2, 37°C). After incubation of 24-72 h, scratch
width is observed under a stereomicroscope. Each
experiment was done three times independently.
Statistical analysis
SPSS statistical software package version 13.0 (SPSS Inc.,
Chicago, IL, USA) was used for all analyses. The Pearson’s
Chi-Square test was used to analyze the relationship be-
tween Btbd7 expression and clinicopathological factors.
The McNemar’s test was used to compare Btbd7 expres-
sion in normal lung tissues and lung cancer tissues. All
data were expressed as means ± standard deviation (S.D.)
for in vitro experiments performed at least 3 times.
P-values of <0.05 were considered statistically significant.
Results
Quantification of Btbd7 expression in NSCLC and
corresponding non-tumor lung tissues
We performed immunohistochemistry (IHC) analysis and
Western blotting study to investigate Btbd7 expression in
NSCLC and corresponding non-tumor lung tissues. The
IHC study shows Btbd7 expression is located mainly in
cytoplasm (Figure 1). Normal bronchial epithelial cells and
submucosal gland cells usually exhibit negative or weak
staining (Figure 1, A, B), while the staining in cancer cells
is often stronger (Figure 1, C, D). Total positive rate of
Btbd7 expression in NSCLC was 51.5% (67/130) and
higher than that in normal lung tissues (11.3%) (6/53) (p <
0.05). Western blotting study confirms increased ex-
pression of Btbd7 in NSCLC tissues compared to lung
tissues (p < 0.05) (Figure 2,A,B). E-cadherin expression
was negatively associated with Btbd7 expression in
these tissues (r = −0.045, p < 0.05) (Figure 2, A, C).
Association between Btbd7 expression and
clinicopathological parameters in NSCLC
The relationship between Btbd7 expression and different
clinicopathological factors in NSCLC is shown in Table 1.
Increased Btbd7 expression in NSCLC was significantly
associated with histological type, lymph node metastasis
and TNM stages (p < 0.05) (Table 1). Higher Btbd7 ex-
pression was found in adenocarcinomas compared to
squamous cell carcinomas (p < 0.05). Btbd7 expression
was higher in cases with lymph node metastasis than
those without lymph node metastasis (p < 0.05). Higher
expression of Btbd7 was also found in cancer with ad-
vanced TNM stages (III + IV) (p < 0.05). There was no
significant association between Btbd7 expression and the
other clinicopathological factors in NSCLC.
Figure 1 Detection of Btbd7 expression using immunohistochemistry. Btbd7 immunostaining was located mainly in cytoplasm. Btbd7
expression in bronchial epithelia (A) and submucosal glands (B) was commonly very weak or absent, while squamous carcinoma (C) and
adenocarcinoma (D) cells often show stronger immunostaining of Btbd7 (×400).
Figure 2 Detection of Btbd7 expression using Western blotting. (A, B) Western blotting study shows increased Btbd7 expression in cancer
tissues (T) compared to corresponding non-tumor lung tissues (N) (* p < 0.05). (A, C) E-cadherin expression was negatively associated with Btbd7
expression in these tissues (r = −0.045, p < 0.05).
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Table 1 Relationship between Btbd7 expression and clinicopathological factors in 130 patients with non-small cell lung cancer
Variables All patients Btbd7 expression
Negative Positive p* X2
Total 130 63 67
Age(y)
<55 47 20 27 0.310 1.029
≥55 83 43 40
Gender
Male 87 44 43 0.493 0.470
Female 43 19 24
Histological type
Squamous cell carcinoma 62 38 24 0.005 7.810
Adenocarcinoma 68 25 43
Grade
Well and moderate 93 47 46 0.453 0.564
Poor 37 16 21
TNM stage
Land II 72 41 31 0.031 4.650
III and IV 58 22 36
Lymph node metastasis
Yes 60 21 39 0.004 8.085
No 70 42 28
*p values were obtained with the X2 test. The bold numbers were considered statistically significant.
Figure 3 Investigation of E-cadherin and N-cadherin expression in non-small cell lung cancer (T) and lung tissues (N) using
immunohistochemistry. Strong and entire membrane expression of E-cadherin was seen in normal bronchial epithelium. Membrane expression
of E-cadherin was decreased in cancer cells. N-cadherin expression was commonly absent in normal bronchial epithelium. Diffuse cytoplasmic
expression of N-cadherin was detected in cancer cells. Strong cytoplasmic Btbd7 expression was accompanied by reduced membrane E-cadherin
expression and accumulation of N-cadherin in cytoplasm in cancer cells (×400).
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Figure 4 The overall Kaplan-Meier survival curves show that
the survival time of patients with Btbd7 expression (39.9 ±
3.5 m) was significantly shorter than that without Btbd7
expression (56.1 ± 4.5 m) (Log rank analysis, p < 0.05).
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E-cadherin and N-cadherin expression in NSCLC
We examined E-cadherin and N-cadherin expression in
NSCLC and non-tumor lung portions using IHC and ana-
lyzed their association with Btbd7 expression. The immu-
nostaning pattern of E-cadherin and N-cadherin is shown
in Figure 3. Normal epithelial cells usually show entire
membrane staining of E-cadherin, while the immunostain-
ing was decreased in cancer cells. Abnormal E-cadherin
expression was seen in 64.6% (51/79) of NSCLC. N-
cadherin was commonly absent in normal epithelial cells.
N-cadherin expression was detected in cancer cells, usu-
ally exhibiting weak to moderate diffuse cytoplasmic stain-
ing. Abnormal cytoplasmic expression of N-cadherin was
seen in 42.9% (27/63) of NSCLC. Relationship between
Btbd7 expression and E-cadherin and N-cadherin status in
NSCLC was shown in Table 2. Btbd7 expression was sig-
nificantly associated with reduced membrane E-cadherin
expression and increased cytoplasmic expression of
N-cadherin in NSCLC (P < 0.05) (Table 2, Figure 3).
Evaluation of Btbd7 as a potential prognostic marker for
NSCLC
We analyzed association between Btbd7 expression and the
survival time of 86 patients with NSCLC. The overall mean
suvival time was 47.1 (±3.0) m. The overall Kaplan-Meier
survival curves reveal correlation between Btbd7 expression
in NSCLC and shorter survival time of patients (p < 0.05).
The survival time of patients with Btbd7 expression (39.9 ±
3.5 m) was significantly shorter than that without Btbd7 ex-
pression (56.1 ± 4.5 m) (p < 0.05) (Figure 4). Multivariate
analysis shows that lymph node metastasis, TNM stage and
Btbd7 expression are independent prognostic markers for
NSCLC (p < 0.05) (Table 3).
Downregulation of Btbd7 restores membrane E-cadherin
expression and inhibits lung cancer cell invasion in vitro
We examined Btbd7 and N-cadherin expression in bron-
chial epithelial HBE cell and lung cancer cell lines includingTable 2 Correlation between Btbd7 expression and
abnormal E-cadherin and N-cadherin expression in






Abnormal 16 35 0.274 0.011
Normal 17 11
N-cadherin
Abnormal 6 21 0.257 0.042
Normal 17 19
*p and rs (correlation coefficient) values were obtained by the Spearman
correlation test.A549, BE1, LK2, NCI-H157, NCI-H460, NCI-H1299, LH7,
LTE and SPC using Western blotting (Figure 5, A, B). Ex-
pression of Btbd7 was detected in these cells with different
levels. Relative higher Btbd7 expression was detected in
NCI-H1299 cells with strong expression of N-cadherin
(Figure 5, A, B). Btbd7 and N-cadherin expression was
positively related in these cell lines (r = 0.095, p < 0.001)
(Figure 5, A, C). Transwell study shows higher invasive
properties in NCI-H1299 cells than those in NCI-H157
cells with relative lower Btbd7 expression (Figure 5, A, B,
D). We used NCI-H1299 cells with higher level of Btbd7
expression to perform in vitro study to investigate the func-
tion of Btbd7 in lung cancer cells. We transfected Btbd7
siRNA to downregulate Btbd7 expression in NCI-H1299
cells. The scratch wounding assay shows that downregula-
tion of Btbd7 using Btbd7 siRNA significantly inhibits the
migration ability of the cells (Figure 6). Western blottingTable 3 Multivariate Cox proportional hazard analysis for
overall survival of 86 patients with non-small cell lung
cancer
B SE Wald df Sig. Exp(B)
Lymph node metastasis .885 .339 6.793 1 .009 2.422
TNM stage .925 .344 7.247 1 .007 2.522
Grade -.479 .345 1.929 1 .165 .620
Btbd7 expression .719 .323 4.961 1 .026 2.052
Age -.131 .303 .187 1 .665 .877
Gender -.200 .306 .430 1 .512 .818
The bold numbers were considered statistically significant.
Figure 5 Detection of Btbd7 expression in lung cancer and bronchial epithelial cell lines. Higher expression level was detected in
NCI-H1299 cells compared to other cancer cell lines and bronchial epithelial cell HBE (A, B); N-cadherin expression was positively associated with
Btbd7 expression (A, C). Relative higher invasive ability (Transwell study, D) was detected in NCI-H1299 cells compared to NCI-H157 cells with
relative lower Btbd7 expression.
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cells significantly upregulated E-cadherin expression and
downregulated snail 2 (slug), MMP2 and MMP7 expression
in cancer cells (Figure 7, A). Immunofluorescent staining
shows effective restoration of membrane expression of
E-cadherin in NCI-H1299 cells after downregulation
of Btbd7 (Figure 7, B).
Discussion
Cancer relapse caused by cancer cell invasion and metasta-
sis is the leading cause of death in patients with malignant
tumors. However, the mechanisms involved in cancer inva-
sion and metastasis are not fully understood yet. E-cadherinis a member of the cadherin superfamily and plays import-
ant roles in the maintenance of intercellular adhesion of
epithelial cells. It is a calcium dependent transmembrane
protein and a key component of adherens junctions [20].
Reduced expression of E-cadherin and dysfunction of E-
cadherin complex in malignant tumors have been reported
and implicated to cancer progression [4,5]. Thus it is
important to fully understand the mechanism involved in
abnormality of E-cadherin expression and its association
with cancer invasion and metastasis for improving lung
cancer therapy based on potential cancer markers.
Yamada et al. found Btbd7 plays an important role in
the branching morphogenesis of salivary glands and
Figure 6 Scratch wounding assay shows downregulation of Btbd7 expression in NCI-H1299 cells using Btbd7 siRNA significantly
inhibits cancer cell migration (* p < 0.05).
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branching of epithelia through the formation of clefts and
buds. Yamada et al’s study shows that highly focal expres-
sion of Btbd7 promotes cell propagation and regulates epi-
thelial cell motility through downregulation of E-cadherin
during cleft formation. Their further study shows that
overexpression of Btbd7 in MDCK (Madin-Darby canine
kidney) cells induced labile cell-cell adhesions and scatter-
ing of MDCK epithelial cell colonies to dispersing cell
clusters in both two-dimensional (2D) cultures and 3D
collagen gels. These data indicate that Btbd7 may function
as a mediator of epithelial dynamics and organ branching.
Btbd7 protein contains two putative BTB/POZ domains.Figure 7 Downregulation of Btbd7 expression in NCI-H1299 cells usin
(A) Western blotting study shows effective downregulation of Btbd7 using
downregulates slug, MMP2 and MMP7 expression (p < 0.05). (B) Immunoflu
cells effectively restores E-cadherin expression in cell membrane (×400).The BTB domain is a protein-protein interaction motif
that determines a unique tri-dimensional fold with a large
interaction surface [16]. Some BTB-containing proteins
are known to control cellular processes including actin dy-
namics and cell-cycle regulation [16]. However, expression
and function of Btbd7 in malignant tumors including lung
cancer are largely unknown so far. In the current study,
we found that expression of Btbd7 at protein level was ele-
vated in NSCLC tissues compared to normal lung tissues.
The pathological analysis shows that overexpression of
Btbd7 in non-small cell lung cancer was associated with
lymph node metastasis and advanced TNM stages, sug-
gesting that Btbd7 may be an important molecule tog Btbd7 siRNA significantly upregulates E-cadherin expression.
Btbd7 siRNA significantly upregulates E-cadherin expression and
orescent staining shows that downregulation of Btbd7 in NCI-H1299
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ever 43.1% of the cases of I + II stages were Btbd7 positive
though the positive rate was lower than that of III + IV.
We can not exclude the possibility of a role of Btbd7 in
early stage of NSCLC. Actually there is a report about
Btbd7 mRNA expression in hepatocarcinoma indicating a
role of Btbd7 to promote cancer cell proliferation though
mechanism involved was not mentioned and not clear.
Here we analyzed the clinical outcome and found that
patients with Btbd7 expression in NSCLC tissues have
shorter survival time than those without Btbd7 expression.
These data indicate that Btbd7 expression may contribute
to patients’ poor clinical outcome of NSCLC and may be a
potential cancer marker for this tumor.
Our immunohistochemistry study shows that Btbd7
expression was associated with reduced membrane expres-
sion of E-cadherin and abnormal cytoplasmic N-cadherin
expression in NSCLC. This result may at least partly ex-
plain its association with lymph node metastasis in NSCLC.
We used siRNA to downregulate Btbd7 expression in lung
cancer cells in vitro to investigate its possible function. We
found that downregulation of Btbd7 using Btbd7 siRNA
significantly inhibits the migration ability of the cells exam-
ined by scratch wounding assay. This result indicates that
Btbd7 may contribute to cancer cell invasion and is consist-
ent with the results in vivo that indicate its association with
lymph node metastasis and patients’ poor clinical outcome.
Our further study shows that downregulation of Btbd7 in
NCI-H1299 cells significantly upregulated E-cadherin
expression in cancer cells. E-cadherin and N-cadherin are
two epithelial-mesenchymal transition (EMT) markers in
cancer cells [21]. These results suggest that Btbd7 may be
involved in EMT of lung cancer cells through regulating
cadherins. The data also indicate that Btbd7 may contribute
to cancer development and patients’ poor clinical outcome
through regulation of E-cadherin and cancer cell dynamics.
However, how exactly Btbd7 functions in this malignant
tumor still needs further investigation. It is important to
reveal mechanism of abnormal E-cadherin expression for
understanding the mechanism of invasion and metastasis
of lung cancer cells and finding new targets for clinical
treatment.
Conclusion
In this study, our findings suggest that the elevated ex-
pression of Btbd7 was a common abnormality in NSCLC
compared to non-tumor portion and could play a role in
NSCLC development including lymph node metastasis
and thus contribute to patients’ poor outcome. Our
study shows that Btbd7 is required for cancer cell inva-
sion. We further demonstrated that Btbd7 expression
was required for lung cancer cell invasion through regu-
lating E-cadherin. These results will provide experimen-
tal evidence for improving lung cancer therapy based onpotential cancer markers. In conclusion, our study pro-
vides evidence that Btbd7 contributes to lung cancer cell
invasion and metastasis through regulating E-cadherin
expression and may be a promising cancer marker.
Additional file
Additional file 1: Relevant clinical data from the patients included
in the study.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CF F, Y M, XP Z, D L, ZH X, L L and EH W participated in the design and case
selection of the study. CF F, XP Z, D L, ZH X, GY J and Y M performed the
experiments including IHC, Western blotting and in vitro study. CF F, Y M
and XY L performed the scoring of immunohistochemical staining. CF F, Y M,
Q H and GY J performed the data analysis and writing of the manuscript. All
the authors read and approved the final manuscript.
Acknowledgement
This work was supported by the National Natural Science Foundation of
China (no. 81071905 to Enhua Wang, MD).
The study was conducted according to the regulations of the institutional
review boards at China.
Received: 9 December 2013 Accepted: 16 September 2014
Published: 24 September 2014
References
1. Zhang PX, Wang Y, Liu Y, Jiang GY, Li QC, Wang EH: P120-catenin isoform
3 regulates subcellular localization of Kaiso and promotes invasion in
lung cancer cells via a phosphorylation-dependent mechanism.
Int J Oncol 2011, 38(6):1625–1635.
2. Yu JH, Miao Y, Xu HT, Liu Y, Jiang GY, Stoecker M, Wang ED, Wang EH:
N-Terminal 1–54 amino acid sequence and armadillo repeat domain rre
indispensable for p120-catenin isoform 1A in regulating E-cadherin.
PloS One 2012, 7(5):e37008.
3. Mays RW, Nelson WJ, Marrs JA: Generation of epithelial cell polarity: roles
for protein trafficking, membrane-cytoskeleton, and E-cadherin-
mediated cell adhesion. Cold Spring Harb Symp Quant Biol 1995,
60:763–773.
4. Mărgineanu E, Cotrutz CE, Cotrutz C: Correlation between E-cadherin
abnormal expressions in different types of cancer and the process of
metastasis. Rev Med Chir Soc Med Nat Iasi 2008, 112(2):432–436.
5. Buda A, Pignatelli M: E-cadherin and the cytoskeletal network in
colorectal cancer development and metastasis. Cell Commun Adhes 2011,
18(6):133–143.
6. Kondo K, Kohno N, Yokoyama A, Hiwada K: Decreased MUC1 expression
induces E-cadherin-mediated cell adhesion of breast cancer cell lines.
Cancer Res 1998, 58(9):2014–2019.
7. El-Hariry I, Pignatelli M, Lemoine NR: FGF-1 and FGF-2 modulate the
E-cadherin/catenin system in pancreatic adenocarcinoma cell lines.
Br J Cancer 2001, 84(12):1656–1663.
8. Jiao W, Miyazaki K, Kitajima Y: Inverse correlation between E-cadherin and
Snail expression in hepatocellular carcinoma cell lines in vitro and
in vivo. Br J Cancer 2002, 86(1):98–101.
9. Pujuguet P, Del Maestro L, Gautreau A, Louvard D, Arpin M: Ezrin regulates
E-cadherin-dependent adherens junction assembly through Rac1
activation. Mol Biol Cell 2003, 14(5):2181–2191.
10. Yang JY, Zong CS, Xia W, Wei Y, Ali-Seyed M, Li Z, Broglio K, Berry DA,
Hung MC: MDM2 promotes cell motility and invasiveness by regulating
E-cadherin degradation. Mol Cell Biol 2006, 26(19):7269–7282.
11. Dupre-Crochet S, Figueroa A, Hogan C, Ferber EC, Bialucha CU, Adams J,
Richardson EC, Fujita Y: Casein kinase 1 is a novel negative regulator of
E-cadherin-based cell-cell contacts. Mol Cell Biol 2007, 27(10):3804–3816.
Fan et al. BMC Cancer 2014, 14:704 Page 10 of 10
http://www.biomedcentral.com/1471-2407/14/70412. Lioni M, Brafford P, Andl C, Rustgi A, El-Deiry W, Herlyn M, Smalley KS:
Dysregulation of claudin-7 leads to loss of E-cadherin expression and
the increased invasion of esophageal squamous cell carcinoma cells.
Am J Pathol 2007, 170(2):709–721.
13. Chetty R, Jain D, Serra S: P120 catenin reduction and cytoplasmic
relocalization leads to dysregulation of E-cadherin in solid pseudopapillary
tumors of the pancreas. Am J Clin Pathol 2008, 130(1):71–76.
14. Hage B, Meinel K, Baum I, Giehl K, Menke A: Rac1 activation inhibits
E-cadherin-mediated adherens junctions via binding to IQGAP1 in
pancreatic carcinoma cells. Cell Commun Signal 2009, 7:23.
15. Onodera T, Sakai T, Hsu JC, Matsumoto K, Chiorini JA, Yamada KM:
Btbd7 regulates epithelial cell dynamics and branching morphogenesis.
Science 2010, 329(5991):562–565.
16. Roberto PT, Daisuke Y, Pierre D: Born to bind:the BTB protein–protein
interaction domain. BioEssays 2006, 28:1194–1202.
17. Goldstraw P, Crowley J, Chansky K: The IASLC lung cancer staging project:
proposals forthe revision of the TNM stage groupings in the
forthcoming (7th) edition of the TNM classification of malignant
tumours. J Thorac Oncol 2007, 2:706–714.
18. Travis WD, Muller-Hermelink HK, Harris CC: World Health Organization
Classification of Tumors: Pathology and Genetics of Tumors of the Lung,
Pleura, Thymus and Heart. Lyon: IARC; 2004.
19. Travis WD, Brambilla E, Noguchi M: International association for the study
of lung cancer/American thoracic society/European respiratory society
international multidisciplinary classification of lung adenocarcinoma.
J Thorac Oncol 2011, 6:244–285.
20. Jawhari A, Farthing M, Pignatelli M: The importance of the E-cadherin-catenin
complex in the maintenance of intestinal epithelial homoeostasis: more
than intercellular glue? Gut 1997, 41(5):581–584.
21. Pallier K, Cessot A, Côté JF, Just PA, Cazes A, Fabre E, Dane C, Riquet M,
Devouassoux-Shisheboran M, Ansieau S, Puisieux A, Laurent-Puig P, Blons H:
TWIST1 a new determinant of epithelial to mesenchymal transition in
EGFR mutated lung adenocarcinoma. PLoS One 2012, 7(1):e29954.
doi:10.1186/1471-2407-14-704
Cite this article as: Fan et al.: Btbd7 contributes to reduced E-cadherin
expression and predicts poor prognosis in non-small cell lung cancer.
BMC Cancer 2014 14:704.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
